Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report)’s stock price gapped down prior to trading on Friday. The stock had previously closed at $35.93, but opened at $31.10. Zealand Pharma A/S shares last traded at $31.10, with a volume of 1,001 shares traded.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on the company. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Zacks Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 10th. Finally, Barclays lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.
Read Our Latest Research Report on Zealand Pharma A/S
Zealand Pharma A/S Trading Down 4.1%
The company has a market cap of $2.18 billion, a price-to-earnings ratio of 4.48 and a beta of 0.99. The company has a quick ratio of 13.98, a current ratio of 13.98 and a debt-to-equity ratio of 0.02. The business’s fifty day simple moving average is $37.43 and its two-hundred day simple moving average is $45.84.
Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.57) by $1.45. The firm had revenue of $0.62 million during the quarter, compared to analysts’ expectations of $1.33 million. Zealand Pharma A/S had a return on equity of 19.70% and a net margin of 67.13%. On average, equities analysts predict that Zealand Pharma A/S will post 5.35 EPS for the current year.
Zealand Pharma A/S Company Profile
Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.
Further Reading
- Five stocks we like better than Zealand Pharma A/S
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
